HEALTH OF WOMAN. 2019.9(145): 76–82
Данная концепция экспертов была разработана Комитетом по Охране здоровья подростков Американского колледжа акушеров и гинекологов в сотрудничестве с членами комитета Jennie Yoost, MD и Ashlyn Savage, MD
Номер 789
Комитет по Охране здоровья подростков
Адаптировано Л.В. Пахаренко

СПИСОК ЛИТЕРАТУРЫ

1. Liu K, Motan T, Claman P. No. 350-hirsutism: evaluation and treatment. J Obstet Gynaecol Can 2017;39:1054–68.

2. Olutunmbi Y, Paley K, English JC 3rd. Adolescent female acne: etiology and management. J Pediatr Adolesc Gynecol 2008;21:171–6.

3. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society [published erratum appears in Hum Reprod Update 2013;19:207]. Hum Reprod Update 2012;18:146–70.

4. Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: Investigations and management. Best Pract Res Clin Obstet Gynaecol 2016;37:98–118.

5. Castelo-Branco C, Cancelo MJ. Comprehensive clinical management of hirsutism. Gynecol Endocrinol 2010;26: 484–93.

6. Witchel SF, Roumimper H, Oberfield S. Polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am 2016;45:329–44.

7. Polycystic ovary syndrome. ACOG Practice Bulletin No. 194. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e157–71.

8. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:73. 945–73.e33.

9. Iezzi ML, Lasorella S, Varriale G, Zagaroli L, Ambrosi M, Verrotti A. Clitoromegaly in childhood and adolescence: behind one clinical sign, a clinical sea. Sex Dev 2018;12: 163–74.

10. Codner E, Villarroel C, Eyzaguirre FC, Lopez P, Merino PM, Perez-Bravo F, et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril 2011;95:702–6.e1–2.

11. Huppert J, Chiodi M, Hillard PJ. Clinical and metabolic findings in adolescent females with hyperandrogenism. J Pediatr Adolesc Gynecol 2004;17:103–8.

12. Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015;136:1154–65.

13. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society. Fertil Steril 2009;91: 456–88.

14. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline [published erratum appears in J Clin Endocrinol Metab 2019;104:39–40]. J Clin Endocrinol Metab 2018;103:4043–88.

15. Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1233–57.

16. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. The Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD007506. DOI: 10. 1002/14651858.CD007506.pub4.

17. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol 2005;192:2055–9.

18. Battaglia C, Mancini F, Fabbri R, Persico N, Busacchi P, Facchinetti F, et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenoneethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010;94:1417–25.

19. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed 2010;8:328–32; quiz 333.

20. Tartagni MV, Alrasheed H, Damiani GR, Montagnani M, De Salvia MA, De Pergola G, et al. Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. J Pediatr Adolesc Gynecol 2014;27:161–5.

21. Obesity in adolescents. Committee Opinion No. 714. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e127–40.

22. Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study [published erratum appears in J Clin Endocrinol Metab 2004;89:4655]. J Clin Endocrinol Metab 2004;89:2756–62.

23. Al Khalifah RA, Florez ID, Dennis B, Thabane L, Bassilious E. Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis. Pediatrics 2016;137:e20154089.

24. Sanchez LA, Perez M, Azziz R. Laser hair reduction in the hirsute patient: a critical assessment. Hum Reprod Update 2002;8:169–81.

25. Fayne RA, Perper M, Eber AE, Aldahan AS, Nouri K. Laser and light treatments for hair reduction in Fitzpatrick skin types IV-VI: a comprehensive review of the literature. Am J Clin Dermatol 2018;19:237–52.

26. Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Eflornithine HCl Study Group. Int J Dermatol 2007; 46:94–8.

27. Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. American Acne and Rosacea Society. Pediatrics 2013;131(suppl 3):163–86.

28. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol 2010;28:17–23.

29. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018;218:88–97.e14.